TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27085434

Group type: EXPERIMENTAL
Intervention: Increased E/SRe ratio
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: E/SRe
Number of subjects: 121

Group type: COMPARATOR
Intervention: E/e' ratio
Number of subjects: 121
Study: 25155138

Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 303

Group type: COMPARATOR
Intervention: No TXA
Number of subjects: 303
Study: 22219414

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 50
Study: 20432816

Group type: EXPERIMENTAL
Intervention: Low dose isoflavone (16 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High dose isoflavone (48 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 12
Study: 17980248

Group type: EXPERIMENTAL
Intervention: Nesiritide (0.01 microg/kg/min with or without a 2-microg/kg bolus)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in water)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 15063404

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP), 750 microg, twice/day for 3 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 28
Study: 12564092

Group type: EXPERIMENTAL
Intervention: 0.5% trimecain infiltration into the thyroid capsule (n = 32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group with saline infiltration into the thyroid capsule (n = 32)
Number of subjects: 64
Study: 9839299

Group type: EXPERIMENTAL
Intervention: 3 MIU of IFN-beta-1a
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 9 MIU of IFN-beta-1a
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: IFN-beta-1a (both doses)
Number of subjects: 49
Study: 8206550

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: No irrigation
Number of subjects: 30
Study: 2674034

Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 10
Study: 5100372

Group type: EXPERIMENTAL
Intervention: Digoxin 0.5 mg oral administration in fasting state
Number of subjects: 21

Group type: COMPARATOR
Intervention: Digoxin 0.5 mg oral administration after food
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Digoxin taken regularly in fasting state
Number of subjects: 21
Study: 31773402

Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials evaluating interventions for osteoporosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions to prevent fractures in osteoporosis
Number of subjects: 0
Study: 29044408

Group type: EXPERIMENTAL
Intervention: Positive psychological skill-building program (6-week duration)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Neutral control activities (6-week duration)
Number of subjects: 42
Study: 26356395

Group type: COMPARATOR
Intervention: Phenazepam monotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Complex treatment with selank and phenazepam
Number of subjects: 70
Study: 23164702

Group type: EXPERIMENTAL
Intervention: Solid fruit preload
Number of subjects: 34

Group type: COMPARATOR
Intervention: Beverage fruit preload
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Solid and beverage fruit and vegetable consumption for 8 weeks
Number of subjects: 34
Study: 21103664

Group type: EXPERIMENTAL
Intervention: Iloprost infusion for one week
Number of subjects: 44
Study: 19748294

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16750985

Group type: EXPERIMENTAL
Intervention: Baseline bronchodilator response
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Baseline log PC20
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Baseline FEV1
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: No controller medications
Number of subjects: 1041
Study: 14571463

Group type: EXPERIMENTAL
Intervention: Strength training (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (n = 7)
Number of subjects: 14
Study: 11081782

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 6614

Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 6614

Group type: COMPARATOR
Intervention: Conventional antihypertensive drugs (diuretics or beta-blockers)
Number of subjects: 6614
Study: 8743589

Group type: EXPERIMENTAL
Intervention: 125 mg caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 250 mg caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Card version of the Stroop task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computerised version of the Stroop task
Number of subjects: 0
Study: 1573097

Group type: EXPERIMENTAL
Intervention: Relaxation imagery training (n = 39)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (n = 37)
Number of subjects: 76
Study: 2860336

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg/puff, 3 times 2 puffs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg/puff, 3 times 3 puffs)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg/puff, 3 times 4 puffs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (3 times 4 puffs)
Number of subjects: 16
Study: 30823944

Group type: EXPERIMENTAL
Intervention: Desloratadine citrate disodium
Number of subjects: 128

Group type: COMPARATOR
Intervention: Loratadine (Control)
Number of subjects: 128
Study: 28295215

Group type: EXPERIMENTAL
Intervention: Surgical trainees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experienced surgeons
Number of subjects: 0
Study: 25852208

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 922

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 922
Study: 24375206

Group type: EXPERIMENTAL
Intervention: LAI risperidone 12.5 to 50 mg per injection biweekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychiatrist's choice of oral antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAI risperidone
Number of subjects: 0
Study: 22025745

Group type: EXPERIMENTAL
Intervention: Telephone care intervention
Number of subjects: 819

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 819
Study: 19117039

Group type: EXPERIMENTAL
Intervention: 3 months of combined flutamide and goserelin before RT
Number of subjects: 378

Group type: COMPARATOR
Intervention: 8 months of combined flutamide and goserelin before RT
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Negative biopsies
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Indeterminate biopsies
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Positive biopsies
Number of subjects: 378
Study: 17143968

Group type: EXPERIMENTAL
Intervention: Reciprocating Procedure Device (RPD)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Conventional Syringe
Number of subjects: 154
Study: 15189958

Group type: EXPERIMENTAL
Intervention: 0.2 ppm O(3)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14
Study: 11375835

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 41

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 41
Study: 9660108

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 300 mg/day
Number of subjects: 11
Study: 7853126

Group type: EXPERIMENTAL
Intervention: Flap debridement plus collagen membrane
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flap debridement alone
Number of subjects: 12
Study: 2551397

Group type: EXPERIMENTAL
Intervention: Intravenous 2-deoxy-D-glucose (2DG) administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncontrollable stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early parental loss
Number of subjects: 0
Study: 1102149

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 16
Study: 31020621

Group type: EXPERIMENTAL
Intervention: Narrative film
Number of subjects: 300

Group type: COMPARATOR
Intervention: Nonnarrative film
Number of subjects: 300
Study: 31441419

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Delayed enteral nutrition (DEN)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: EEN
Number of subjects: 34

Group type: COMPARATOR
Intervention: DEN
Number of subjects: 34
Study: 28731984

Group type: EXPERIMENTAL
Intervention: Smoking (recently smoked cigarettes)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 149
Study: 25175554

Group type: EXPERIMENTAL
Intervention: Acupressure massage three times a week for 30 minutes on the sanyinjiao (SP6), ciliao (BL32), and taichong (Liver 3) acupoints.
Number of subjects: 129

Group type: COMPARATOR
Intervention: Manual of menstrual health education (Control group).
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Acupressure intervention (Experimental group).
Number of subjects: 129
Study: 23908318

Group type: EXPERIMENTAL
Intervention: HMB-FA
Number of subjects: 40

Group type: COMPARATOR
Intervention: CWI
Number of subjects: 40

Group type: COMPARATOR
Intervention: PL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HMB-FA-CWI
Number of subjects: 40
Study: 21741469

Group type: EXPERIMENTAL
Intervention: ArtTear
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shampoo A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shampoo B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shampoo C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shampoo D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shampoo E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lacrimation
Number of subjects: 0
Study: 19560329

Group type: EXPERIMENTAL
Intervention: Baseline n-3 PUFA status
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-depressed controls
Number of subjects: 0
Study: 16436081

Group type: EXPERIMENTAL
Intervention: Feedback-plus (FB+) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback (FB) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 14689241

Group type: EXPERIMENTAL
Intervention: Logan's non-invasive graphical analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simplified reference tissue method (SRTM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interindividual averaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monte Carlo simulations
Number of subjects: 0
Study: 11551575

Group type: EXPERIMENTAL
Intervention: Oral immune‐enhancing nutritional supplement containing L‐arginine, omega-3 polyunsaturated fatty acids, and yeast RNA (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo) (n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral immune‐enhancing nutritional supplement (n=25)
Number of subjects: 50
Study: 9243688

Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation through a laryngeal mask
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation through a tracheal tube
Number of subjects: 60
Study: 8330828

Group type: EXPERIMENTAL
Intervention: 2.4 mg glycerol trinitrate (GTN) administered in various forms (2 x 1.2 mg capsules; 6 x 0.4 mg puffs of an atomizer; 2.4 ml of an 0.1% infusion solution)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 20 mg of butylscopolamine bromide i.v. (BSB)
Number of subjects: 80
Study: 6101174

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily for two weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30250241

Group type: EXPERIMENTAL
Intervention: FASTED
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FED
Number of subjects: 12
Study: 24203774

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 27472478

Group type: EXPERIMENTAL
Intervention: Formula with scGOS/lcFOS
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS + 15% FERM
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS + 50% FERM
Number of subjects: 432

Group type: COMPARATOR
Intervention: 50% fermented formula (50% FERM)
Number of subjects: 432
Study: 24395308

Group type: EXPERIMENTAL
Intervention: Low offset femoral group
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Normal offset femoral group
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: High offset femoral group
Number of subjects: 362
Study: 22275157

Group type: COMPARATOR
Intervention: Actual Amount of Use Test (AAUT) quality of movement (AAUTq)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor Activity Log (MAL) quality of movement (MALq)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Actual Amount of Use Test (AAUT) amount of use (AAUTa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor Activity Log (MAL) amount of use (MALa)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training-induced spontaneous arm use
Number of subjects: 0
Study: 19223520

Group type: EXPERIMENTAL
Intervention: Modified-release hydrocortisone (MR-HC) 15 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Immediate-release hydrocortisone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Modeling of MR-HC
Number of subjects: 28
Study: 17557991

Group type: EXPERIMENTAL
Intervention: Increased portion sizes (50% increase)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard portion sizes
Number of subjects: 23
Study: 16827683

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based therapy (n = 33)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cyclosporine microemulsion-based therapy (n = 33)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 12944209

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 50
Study: 10026457

Group type: EXPERIMENTAL
Intervention: Expatriate employees (n = 47)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Matched non-moving reference group (n = 35)
Number of subjects: 47
Study: 8689806

Group type: EXPERIMENTAL
Intervention: 2 mg buprenorphine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 mg buprenorphine and 2 mg naloxone combined
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 2 mg naloxone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1660610

Group type: EXPERIMENTAL
Intervention: Isoproterenol (0.1, 0.25, 0.5, 1.0, 2.0, and 4.0 micrograms)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 6346939

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with 0.2% bupivacaine at 0.2 ml/kg.h for 24 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neuroleptanalgesia with postoperative Piritramid
Number of subjects: 30
Study: 31319188

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) based on 7 variables: age, tumor site, sex, marital status, histological type, tumor size, and surgery.
Number of subjects: 3732
Study: 27930408

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 1476

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1476
Study: 25792802

Group type: COMPARATOR
Intervention: Transdermal donepezil patch (43.75 mg/12.5 cm², 87.5 mg/25 cm², 175 mg/50 cm²)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Transdermal donepezil patch
Number of subjects: 36
Study: 23506277

Group type: EXPERIMENTAL
Intervention: 127.2 mg lidocaine with 50 μg epinephrine plus 0.5 M mannitol (5 mL formulation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 127.2 mg lidocaine with 50 μg epinephrine (3.18 mL formulation)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both formulations (lidocaine with and without mannitol)
Number of subjects: 40
Study: 21455087

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg) given at 2 doses 8 hrs apart
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and placebo
Number of subjects: 30
Study: 19653988

Group type: EXPERIMENTAL
Intervention: STD-14 (0.25 mg/kg/day for 14 days)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: STD-3 (0.25 mg/kg/day for 3 days)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 71%STD-3 (0.178 mg/kg/day for 3 days)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 50%STD-3 (0.125 mg/kg/day for 3 days)
Number of subjects: 188
Study: 17056362

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 0
Study: 14652116

Group type: EXPERIMENTAL
Intervention: Newly designed anesthesiology preoperative evaluation form
Number of subjects: 0
Study: 10694547

Group type: EXPERIMENTAL
Intervention: Single-dose total-body irradiation (STBI) - 10 Gy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Hyperfractionated total-body irradiation (HTBI) - 14.85 Gy
Number of subjects: 160
Study: 9066326

Group type: EXPERIMENTAL
Intervention: Induction of propofol/desflurane anesthesia
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Vasodilation from warming and vasoconstriction from cooling
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ambient temperature variation (18-26 degrees C)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Core-to-forehead temperature difference
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Core-to-neck temperature difference
Number of subjects: 7
Study: 8259746

Group type: EXPERIMENTAL
Intervention: Labetalol (Group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hydralazine (Group B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both drugs (Group C)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 22
Study: 3891378

Group type: EXPERIMENTAL
Intervention: Slow-release furosemide 60 mg daily
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Slow-release furosemide 30 mg daily
Number of subjects: 86

Group type: COMPARATOR
Intervention: Bendroflumethiazide 2.5 mg daily
Number of subjects: 86
Study: 30091852

Group type: COMPARATOR
Intervention: AG-348 (30-2500 mg single dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: AG-348 (15-700 mg every 12 hours or 120 mg every 24 hours for 14 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29909400

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at bilateral BL32, BL33, and BL35, once a day for the first 4 weeks, then once every other day for the following 4 weeks.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) for bowel dysfunction.
Number of subjects: 16
Study: 25760277

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Otago
Number of subjects: 45
Study: 25453528

Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy (CST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Light touch sham-control intervention
Number of subjects: 50
Study: 22901362

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d; mean dose = 13.5 mg/d)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Lithium (300-1,800 mg/d; mean dose = 1,003.3 mg/d)
Number of subjects: 431
Study: 20096647

Group type: EXPERIMENTAL
Intervention: II-SG
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: II-DSG
Number of subjects: 38
Study: 17872488

Group type: EXPERIMENTAL
Intervention: Endotracheal tube with polyurethane cuff and subglottic secretion drainage (ETT-PUC-SSD)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Conventional endotracheal tube (ETT-C) with polyvinyl cuff, without subglottic secretion drainage
Number of subjects: 280

Group type: COMPARATOR
Intervention: ETT-C
Number of subjects: 280
Study: 15910516

Group type: EXPERIMENTAL
Intervention: 5 mg melatonin administered at 18:00 or 19:00 hours
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo administered at 18:00 or 19:00 hours
Number of subjects: 110
Study: 11459433

Group type: EXPERIMENTAL
Intervention: iloprost (0.5‐2 ng/kg/h i.v. infused, 6 h/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: supervised physical exercise
Number of subjects: 24
Study: 9517367

Group type: EXPERIMENTAL
Intervention: Single oral dose of carbamazepine (200-800 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Multiple dosing of carbamazepine (400-800 mg twice daily for 14 days)
Number of subjects: 60
Study: 8038904

Group type: EXPERIMENTAL
Intervention: Sodium valproate (600 mg in three divided doses orally)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Naloxone (10 mg as an iv bolus injection)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Naloxone plus sodium valproate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3177753

Group type: EXPERIMENTAL
Intervention: Suppressive therapy
Number of subjects: 431

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 431
Study: 31012853

Group type: EXPERIMENTAL
Intervention: PFT-guided de-escalation of dual antiplatelet therapy (DAPT)
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Standard treatment with prasugrel for 12 months (control group)
Number of subjects: 2610

Group type: COMPARATOR
Intervention: Control group (prasugrel)
Number of subjects: 2610

Group type: EXPERIMENTAL
Intervention: Guided de-escalation group (clopidogrel)
Number of subjects: 2610
Study: 28337847

Group type: EXPERIMENTAL
Intervention: BT + EA
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: BT
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: BT + E
Number of subjects: 283